Advanced search×

Biological and clinical aspects of plasminogen activator inhibitor type 2.

E K Kruithof, M S Baker, and C L Bunn

Blood 86(11):4007-24 (1995) PMID 7492756

Version: za2963e q8zab q8zb7 q8zcc q8zd2 q8ze8 q8zf6 q8zg8

Similar articles you may find interesting…

  1. Macular pigment optical density in an ageing Irish population: The Irish Longitudinal Study on Ageing.
    John M Nolan, Roseanne Kenny, ... Stephen Beatty

    Ophthalmic Res 44(2):131-9 (2010) PMID 20516725

    We report an inverse association between MPOD and increasing age. Longitudinal data in a larger cohort of participants are required to satisfactorily investigate the relationship between the optical density of this pigment and age, and with risk for development and/or progression of AMD. This pilot...
  2. Impact of once daily versus twice daily application of adjunctive timolol on the intraocular pressure-lowering effect of latanoprost.
    Mohammad H Nowroozzadeh

    Ophthalmic Res 44(2):140 (2010) PMID 20516726

  3. Evaluation of succinylated collagen bandage lenses in corneal healing by the expression of matrix metalloproteinases (MMP-2 and MMP-9) in te...
    J J Hadassah, Namita N Bhuvaneshwari, ... P K PK Sehgal

    Audio, Transactions of the IRE Professiona... 42(2):64-72 (2009) PMID 19478544

    Subjective clinical assessment of CU, RCE, DE and CL patients after treatment with SCBL showed significant reduction in the symptoms, patients felt comfortable with SCBL with no change in visual acuity, indicating complete transparency of SCBL. Protein content was very high on day 1 among all the pa...